SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure
March 12 2024 - 7:14AM
SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty
clinical-stage pharmaceutical company focusing on the development
of therapies to treat disorders of the central nervous system,
today announced that MitoCareX Bio Ltd. ("MitoCareX "), the
Company’s venture with Dr. Alon Silberman that focuses on drug
discovery and the development of cancer therapeutics by targeting
the mitochondrial SLC25 protein family, revealed that millions of
small molecules were virtually screened using its computationally
advanced drug discovery platform, with several molecules identified
as potential anti-cancer treatments.
By using its in-vitro screening systems related to the
mitochondria, MitoCareX corroborated its virtual findings by
confirming the anti-cancer biological activity of several small
molecule structures.
Additionally, by utilizing the extensive virtual data generated,
MitoCareX working towards creating a predictive AI model. This
model is expected to enable MitoCareX to navigate broader chemical
spaces more efficiently, with the goal of uncovering more novel
anti-cancer scaffolds that target its SLC25 protein of
interest.
About SciSparc Ltd. (Nasdaq:
SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical
company led by an experienced team of senior executives and
scientists. SciSparc’s focus is on creating and enhancing a
portfolio of technologies and assets based on cannabinoid
pharmaceuticals. With this focus, the Company is currently engaged
in the following drug development programs based on THC and/or
non-psychoactive CBD: SCI-110 for the treatment of Tourette
Syndrome, for the treatment of Alzheimer's disease and agitation;
SCI-160 for the treatment of pain; and SCI-210 for the treatment of
ASD and status epilepticus. The Company also owns a controlling
interest in a subsidiary whose business focuses on the sale of hemp
seeds’ oil-based products on Amazon Marketplace.
Forward-Looking Statements:
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. For example, SciSparc is using forward-looking
statements when it discusses that MitoCareX is working towards
creating a predictive AI model and that such model is expected to
enable MitoCareX to navigate broader chemical spaces more
efficiently, with the goal of uncovering more novel anti-cancer
scaffolds that target the SLC25 protein of interest. Historical
results of scientific research and clinical and preclinical trials
do not guarantee that the conclusions of future research or trials
will suggest identical or even similar conclusions. Because such
statements deal with future events and are based on SciSparc's
current expectations, they are subject to various risks and
uncertainties and actual results, performance or achievements of
SciSparc could differ materially from those described in or implied
by the statements in this press release. The forward-looking
statements contained or implied in this press release are subject
to other risks and uncertainties, including those discussed under
the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F
filed with the SEC on May 1, 2023, and in subsequent filings
with the U.S. Securities and Exchange Commission. Except as
otherwise required by law, SciSparc disclaims any intention or
obligation to update or revise any forward-looking statements,
which speak only as of the date they were made, whether as a result
of new information, future events or circumstances or
otherwise.
Investor Contact:IR@scisparc.comTel:
+972-3-6167055
SciSparc (NASDAQ:SPRC)
Historical Stock Chart
From Aug 2024 to Sep 2024
SciSparc (NASDAQ:SPRC)
Historical Stock Chart
From Sep 2023 to Sep 2024